A Chinese cohort study identifies factors associated with prognosis among patients with connective tissue disease-associated pulmonary arterial hypertension.
Evaluation of pulmonary arterial compliance after initiation or escalation of therapy for pulmonary arterial hypertension more accurately predicts prognosis than conventional right heart hemodynamic parameters, Italian study findings indicate.
A post-hoc subgroup analysis of the AMBITION trial suggests that the benefits of ambrisentan and tadalafil combination therapy extend to patients with connective tissue disease-associated pulmonary arterial hypertension.
Research published in the Journal of the American College of Cardiology suggests that there could be a pathophysiological overlap between combined post-capillary and pre-capillary pulmonary hypertension and pulmonary arterial hypertension.
N-terminal pro-B-type natriuretic peptide may be more accurate than B-type natriuretic peptide for detecting and monitoring pulmonary arterial hypertension in patients with systemic sclerosis, study findings suggest.
Pulmonary arterial hypertension-related hospitalization rates have fallen significantly in the USA since 2001, but the cost of each hospitalization has risen substantially and is increasingly paid for by Medicare, study findings indicate.
A single bout of exercise causes immediate changes in circulating T lymphocyte levels and improvements in the altered cytokine profile of patients with idiopathic pulmonary arterial hypertension, without aggravating the inflammatory state, researchers report.
The risk for death increases with increasing diastolic pulmonary gradient in patients with World Health Organization group 1 pulmonary hypertension, American research suggests.
Around one-third of patients with idiopathic pulmonary arterial hypertension may have an undiagnosed connective tissue disease, according to Italian researchers.
Reduced nitric oxide synthesis appears to play a role in the pathogenesis of idiopathic pulmonary arterial hypertension and measuring plasma levels of the resulting nitrate and nitrite metabolites could help predict outcome, research suggests.
An Australian research team has pinpointed several clinical and serologic parameters that identify systemic sclerosis patients at risk of developing pulmonary arterial hypertension.
A post-hoc analysis of the AMBITION trial raises the possibility that upfront combination therapy could have a beneficial effect on the survival of patients with pulmonary arterial hypertension.
Including gas exchange measurements during the 6-minute walk distance test may give a better indication of disease severity in patients with pulmonary arterial hypertension than the walk test alone, researchers report.
Patients with multiple mutations in genes linked to pulmonary artery hypertension have severe disease and a poor response to treatment, report researchers.
Performing right heart catheterisation to classify pulmonary arterial hypertension ahead of initiating medication, in line with consensus guidelines, does not appear to be carried out as often as it should, findings from a US-based population suggest.
Researchers have developed the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT®) questionnaire, which they say captures symptoms and impacts relevant to the patient population.
Analysis of the VOLibris Tracking post-marketing registry shows no new safety issues for ambrisentan used in patients with pulmonary arterial hypertension.